Making the compound Amanitin available for cancer therapies
Our mission is to research and develop drugs for cancer patients to provide them
with a targeted, tailor-made and highly effective treatment option
ADC Drug Development
We use the active ingredient Amanitin from the death cap mushroom for cancer therapies by researching, producing and clinically developing so-called Antibody Amanitin Conjugates.
ATACs belong to the class of Antibody Drug Conjugates (ADCs), which combine the high affinity and specificity of antibodies with the efficacy of small toxic molecules to fight cancer.
PR: Heidelberg Pharma Announces Changes to the Executive Management Board
AH: Heidelberg Pharma Announces Changes to the Executive Management Board
PR: Heidelberg Pharma Secures Patent for the Use of its ADC Technology Platform
PR: Heidelberg Pharma Presents New Clinical Data from its Lead Candidate HDP-101 at the ASH Annual Meeting 2023